UK Markets closed

ObsEva SA (OBSV)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.7700+0.1000 (+5.99%)
At close: 04:00PM EDT
1.7700 0.00 (0.00%)
After hours: 07:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.6700
Open1.7600
Bid1.6800 x 1400
Ask1.7700 x 1400
Day's range1.6900 - 1.7750
52-week range1.0800 - 3.5800
Volume203,871
Avg. volume502,138
Market cap138.01M
Beta (5Y monthly)0.73
PE ratio (TTM)N/A
EPS (TTM)-0.8220
Earnings date03 Mar 2022 - 07 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.38
  • Globe Newswire

    ObsEva Announces Corporate Updates

    Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced today that it has entered into a waiver and amendment agreement (Amendment Agreement) with respect to its amended and restated securities purchase agreement (Securities Purchase Agreement) with certain funds and accounts managed by JGB Management, Inc.

  • Globe Newswire

    ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses

    -Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th World Congress- GENEVA, Switzerland May 25, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the presentation of clinical data on linzagolix, an oral GnRH antagonist. These data were featured in

  • Globe Newswire

    ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors

    GENEVA, Switzerland May 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment of Annette Clancy as Chair of the Board of Directors at the Company’s Annual General Meeting on May 18, 2022. Ms. Clancy has served as a member of ObsEva’s Board of Directors since 2013 and was previously Chair from November 2013 to December 2016. Ms. Clancy succeeds Dr. Frank Verwiel, who had decide